Literature DB >> 25540737

Role of liver transplantation in the management of hepatoblastoma in the pediatric population.

Saira Khaderi1, Jacfranz Guiteau1, Ronald T Cotton1, Christine O'Mahony1, Abbas Rana1, John A Goss1.   

Abstract

Hepatoblastoma (HB) is the most common primary liver tumor in children and accounts for two-thirds of all malignant liver neoplasms in the pediatric population. For patients with advanced HB (unresectable or unresponsive to chemotherapy), combined treatment with chemotherapy and liver transplantation is an excellent option. The etiology of HB is mostly obscure because of its extreme rarity although some inherited syndromes and very low birth weight have been associated with it. The prognosis for children with HB has significantly improved in the past three decades thanks to advancements in chemotherapy, surgical resection and postoperative care. In 2002 a surgical staging system called pretreatment extent of disease (PRETEXT) was designed to allow a universal, multidisciplinary approach to patients with HB. Between one-third to two-thirds of patients initially present with unresectable tumors or distant metastases, but up to 85% of these tumors become operable after neoadjuvant chemotherapy. Patients with PRETEXT categories 1, 2, and some 3 are referred for neoadjuvant chemotherapy followed by surgical resection with the goal of complete tumor removal. Classic treatments regimens include a combination of cisplatin, fluorouracil, and vincristine or cisplatin and doxorubicin. Liver transplantation is the only treatment option for unresectable HB. In 2010 the pediatric end-stage liver disease, a pediatric-specific scoring system that determines a patient's ranking on the liver transplant list, began to award additional "exception" points for patients with HB. We analyzed the Standard Transplant Analysis and Research dataset to assess the impact of changes in exception point criteria for HB on outcomes after liver transplantation at Texas Children's Hospital in Houston, Texas. We found that patients who were listed for transplantation with current HB exception criteria experienced a shorter waitlist time but survival was similar between the two eras.

Entities:  

Keywords:  Cancer; Chemotherapy; Hepatoblastoma; Liver transplant; Pediatric

Year:  2014        PMID: 25540737      PMCID: PMC4274598          DOI: 10.5500/wjt.v4.i4.294

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  17 in total

Review 1.  Iatrogenic environmental hazards in the neonatal intensive care unit.

Authors:  Thomas T Lai; Cynthia F Bearer
Journal:  Clin Perinatol       Date:  2008-03       Impact factor: 3.430

2.  Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years.

Authors:  Hor Ismail; Dorota Broniszczak; Piotr Kaliciński; Bożenna Dembowska-Bagińska; Danuta Perek; Joanna Teisseyre; Przemyslaw Kluge; Andrzej Kościesza; Agnieszka Lembas; Malgorzata Markiewicz
Journal:  J Pediatr Surg       Date:  2012-07       Impact factor: 2.545

Review 3.  Oxygen toxicity in premature infants.

Authors:  Barry Weinberger; Debra L Laskin; Diane E Heck; Jeffrey D Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2002-05-15       Impact factor: 4.219

4.  Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

5.  Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry.

Authors:  M R DeBaun; M A Tucker
Journal:  J Pediatr       Date:  1998-03       Impact factor: 4.406

6.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.

Authors:  József Zsíros; Rudolf Maibach; Elizabeth Shafford; Laurence Brugieres; Penelope Brock; Piotr Czauderna; Derek Roebuck; Margaret Childs; Arthur Zimmermann; Veronique Laithier; Jean-Bernard Otte; Beatriz de Camargo; Gordon MacKinlay; Marcelo Scopinaro; Daniel Aronson; Jack Plaschkes; Giorgio Perilongo
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

7.  Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.

Authors:  Giorgio Perilongo; Rudolf Maibach; Elisabeth Shafford; Laurence Brugieres; Penelope Brock; Bruce Morland; Beatriz de Camargo; Jozsef Zsiros; Derek Roebuck; Arthur Zimmermann; Daniel Aronson; Margaret Childs; Eva Widing; Veronique Laithier; Jack Plaschkes; Jon Pritchard; Marcello Scopinaro; Gordon MacKinlay; Piotr Czauderna
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 8.  Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience.

Authors:  J B Otte; J Pritchard; D C Aronson; J Brown; P Czauderna; R Maibach; G Perilongo; E Shafford; J Plaschkes
Journal:  Pediatr Blood Cancer       Date:  2004-01       Impact factor: 3.167

Review 9.  Liver tumors in children.

Authors:  Jason B Litten; Gail E Tomlinson
Journal:  Oncologist       Date:  2008-07-21

10.  Single-agent cisplatin treatment of children with high-risk hepatoblastoma.

Authors:  Yu-Tong Zhang; Li-Hua Feng; Xiao-Dan Zhong; Li-Zhe Wang; Jian Chang
Journal:  J Pediatr Hematol Oncol       Date:  2014-05       Impact factor: 1.289

View more
  9 in total

1.  Resolvin D1 inhibits the proliferation of lipopolysaccharide-treated HepG2 hepatoblastoma and PLC/PRF/5 hepatocellular carcinoma cells by targeting the MAPK pathway.

Authors:  You Lu; Qingyu Xu; Guowen Yin; Weidong Xu; Hao Jiang
Journal:  Exp Ther Med       Date:  2018-08-23       Impact factor: 2.447

Review 2.  Pediatric liver transplantation for hepatoblastoma.

Authors:  Angela D Trobaugh-Lotrario; Rebecka L Meyers; Greg M Tiao; James H Feusner
Journal:  Transl Gastroenterol Hepatol       Date:  2016-05-20

3.  Biliary complications in liver transplantation: Impact of anastomotic technique and ischemic time on short- and long-term outcome.

Authors:  Stefan Kienlein; Wenzel Schoening; Anne Andert; Daniela Kroy; Ulf Peter Neumann; Maximilian Schmeding
Journal:  World J Transplant       Date:  2015-12-24

4.  CXCL5 as an autocrine or paracrine cytokine is associated with proliferation and migration of hepatoblastoma HepG2 cells.

Authors:  Yang Yang; Jie Hou; Mingliang Shao; Wei Zhang; Yaling Qi; Shengnan E; Shuqiu Wang; Hongyu Sui; Dexin Meng; Baixin Wang; Mingfu Wang; Yang Han; Yu Cao; Xiaoqing Huang; Yue Li; Pengxia Zhang; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

5.  Periostin mediates epithelial-mesenchymal transition through the MAPK/ERK pathway in hepatoblastoma.

Authors:  Lu Chen; Xiangdong Tian; Wenchen Gong; Bo Sun; Guangtao Li; Dongming Liu; Piao Guo; Yuchao He; Ziye Chen; Yuren Xia; Tianqiang Song; Hua Guo
Journal:  Cancer Biol Med       Date:  2019-02       Impact factor: 4.248

6.  Volasertib preclinical activity in high-risk hepatoblastoma.

Authors:  Stefano Cairo; Charles Keller; Dina Kats; Cora A Ricker; Noah E Berlow; Bénédicte Noblet; Delphine Nicolle; Katell Mevel; Sophie Branchereau; Jean-Gabriel Judde; Cody D Stiverson; Christina L Stiverson; Matthew N Svalina; Teagan Settelmeyer; Kevin Matlock; Melvin Lathara; Charlotte Mussini; James I Geller; Christopher Noakes; Ido Sloma; Narendra Bharathy
Journal:  Oncotarget       Date:  2019-11-05

Review 7.  Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies.

Authors:  Rishi Raj Rikhi; Kimberlee K Spady; Ruth I Hoffman; Michael S Bateman; Max Bateman; Lisa Easom Howard
Journal:  Front Pediatr       Date:  2016-03-21       Impact factor: 3.418

8.  Effects of ginkgol C17:1 on cisplatin-induced autophagy and apoptosis in HepG2 cells.

Authors:  Jun Liu; Yueying Li; Xiaoming Yang; Yan Dong; Jing Wu; Min Chen
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

Review 9.  Hepatoblastoma with pure fetal epithelial differentiation in a 10-year-old boy: A rare case report and review of the literature.

Authors:  Shanshan Zhong; Yang Zhao; Chuifeng Fan
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.